Skip to main content
Equibles
TRAW logo

TRAW · Traws Pharma, Inc. · Analyst Estimates

Track TRAW — free

Use TRAW with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TRAW.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.56 +0.03 (+6.17%) At close · Sep 11
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on current projections, the Company believes that it does not have sufficient cash and cash equivalents to support its operations for more than one year following the date that these financial statements are issued. As a result of these conditions, substantial doubt exists about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$8.67M
Shares
15.37M

Analyst Estimates

Compare analyst forecasts for Traws Pharma, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Only independently verified consensus published through the company's investor-relations sources is available.

Consensus not yet available

Only independently verified consensus published through the company's investor-relations sources is available.

Key facts CIK 1130598 CUSIP 68232V884 13F (30d) 26 filings 26 filers Visit website Investor relations